Nuclear translocation of AMPK-α1 potentiates striatal neurodegeneration in Huntington’s disease by Ju, Tz-Chuen et al.
JCB: Article
The Rockefeller University Press    $30.00
J. Cell Biol. Vol. 194 No. 2  209–227
www.jcb.org/cgi/doi/10.1083/jcb.201105010 JCB 209
Correspondence to Yijuang Chern: bmychern@ibms.sinica.edu.tw
Abbreviations used in this paper: AAV, adeno-associated virus; AD, Alzheimer’s 
disease; AICAR, aminoimidazole carboxamide riboside; AMPK, AMP-activated 
protein kinase; CC, compound C; CREB, cAMP response element binding; CSC, 
8-[-3-chlorostyryl]-caffeine;  GAPDH,  glyceraldehyde-3-phosphate  dehydroge-
nase; HD, Huntington’s disease; hrGFP, humanized Renilla GFP; Htt, Huntingtin; 
mHtt, mutant Htt; MRI, magnetic resonance imaging; NES, nuclear export sig-
nal; NeuN, neuronal nuclei; PARP, poly (ADP-ribose) polymerase; PB, phosphate 
buffer; polyQ, polyglutamine; qPCR, quantitative PCR; RIPA, radioimmunoprecipita-
tion assay; VBR, ventricle to brain ratio; WT, wild type.
Introduction
Huntington’s disease (HD) is an autosomal dominant neuro­
degenerative disease that manifests clinically as progressive 
involuntary movement disorders, dementia, and eventual death 
(Martin and Gusella, 1986). It is caused by CAG trinucleotide 
expansion in exon 1 of the huntingtin (Htt) gene. When the 
number of CAG repeats exceeds 36, the translated polygluta­
mine (polyQ) containing the Htt protein (mutant Htt [mHtt]) 
interferes with the normal functions of many cellular pro­
teins and subsequently jeopardizes important cellular machin­
ery (The Huntington’s Disease Collaborative Research Group, 
1993; Landles and Bates, 2004; Buckley et al., 2010). Severe 
tissue damage is observed in the neostriatum, nigrostriatal tract, 
and cortex (Estrada Sánchez et al., 2008).
In addition to neuronal dysregulation, metabolic abnormal­
ities are another important hallmark of HD (Pratley et al., 2000). 
Hyperglycemia  and  abnormal  glucose  metabolism  were  ob­
served in several mouse models of HD and in patients with HD 
(Hurlbert et al., 1999). Deficiencies in several other metabolic 
pathways (e.g., cholesterol biosynthesis and urea cycle metabo­
lism) are also well documented (Chiang et al., 2007; Valenza 
et al., 2007). AMP­activated protein kinase (AMPK) is a major 
energy sensor that regulates an array of downstream target genes 
and maintains cellular energy homeostasis by activating energy 
production and inhibiting energy expenditure in many different 
tissues (Long and Zierath, 2006). AMPK comprises three sub­
units (, , and ) and can be activated by several upstream 
kinases (CaM­dependent protein kinase kinase [CaMKK] and 
LKB1) via the phosphorylation of its Thr residue 172 within the 
catalytic domain of the  subunit (Stein et al., 2000). Other kinases 
(including the cAMP­dependent kinase [PKA] and Ca
2+/CaM­
dependent  protein  kinase  II  [CaMKII])  were  also  shown  to   
regulate the activity of AMPK (Hurley et al., 2006; Raney and 
Turcotte, 2008). The  subunit of AMPK is the catalytic subunit 
and has at least two different isoforms (1 and 2). AMPK­1 
is predominantly expressed in the cytoplasm, whereas the   
A
denosine  monophosphate–activated  protein  ki-
nase (AMPK) is a major energy sensor that main-
tains  cellular  energy  homeostasis.  Huntington’s 
disease (HD) is a neurodegenerative disorder caused by 
the expansion of CAG repeats in the huntingtin (Htt) gene. 
In this paper, we report that activation of the 1 isoform 
of  AMPK  (AMPK-1)  occurred  in  striatal  neurons  of   
humans and mice with HD. Overactivation of AMPK in the 
striatum caused brain atrophy, facilitated neuronal loss, 
and increased formation of Htt aggregates in a transgenic 
mouse model (R6/2) of HD. Such nuclear accumulation of 
AMPK-1 was activity dependent. Prevention of nuclear 
translocation or inactivation of AMPK-1 ameliorated cell 
death and down-regulation of Bcl2 caused by mutant Htt 
(mHtt). Conversely, enhanced expression of Bcl2 protected 
striatal cells from the toxicity evoked by mHtt and AMPK 
overactivation. These data demonstrate that aberrant   
activation of AMPK-1 in the nuclei of striatal cells repre-
sents a new toxic pathway induced by mHtt.
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Figure 1.  Selective activation and nuclear enrichment of AMPK-1 in striatal neurons of patients and mice with HD. (A and B) The caudate nucleus (A) 
and frontal cortex (B) of HD patients and age-matched controls were analyzed. Immunofluorescence staining of AMPK--p (green) or AMPK-1 (green) was 
conducted. (C and D) Immunofluorescence staining of AMPK--p (C, green) or AMPK-1 (D, green) was conducted in brains of 12-wk-old mice. Nuclei were 211 Functional roles of AMPK in Huntington’s disease • Ju et al.
To verify whether mHtt directly regulates AMPK in stria­
tal cells, the activation of AMPK in the presence of mHtt was 
evaluated in three striatal cell lines. The level of AMPK­­p 
was higher in STHdh
Q109 cells, which carry the polyQ­expanded 
mouse gene Htt, than in the control cell line (STHdh
Q7), which 
encodes seven CAG repeats in the Htt gene (Fig. 2 A). Simi­
larly, the transient expression of Htt­(Q)109–humanized Renilla 
GFP (hrGFP; 109Q) in ST14A cells caused a higher level of 
AMPK phosphorylation than did the expression of Htt­(Q)25­
hrGFP (25Q; Fig. 2 B). A similar result of activated AMPK­ 
was also observed in the striatum of both male and female R6/2 
mice (Figs. 2 C and S1 D). Moreover, AMPK activation and nu­
clear location of AMPK­1 in the brain of mice and patients 
with HD showed no gender differences (Figs. 1 [A and B] and 
S1 [A–D]).
Next,  we  performed  experiments  to  identify  the  entity   
in the AMPK­ subunit that is regulated by mHtt. Immuno­
precipitation of AMPK­1 revealed that the phosphorylation of 
AMPK­1 at Thr
172 was significant in the striatum of R6/2 mice, 
whereas it was barely detectable in that of WT mice (Fig. 1 E). 
No change in the phosphorylation status of AMPK­2 at Thr
172 
was detected in the striatum of either WT or R6/2 mice (Fig. 1 F). 
Consistent with these findings, Western blot analyses of frac­
tionated striatal proteins harvested from 12­wk­old WT and R6/2 
mice showed that AMPK­1 and AMPK­­p were largely lo­
cated in the striatal nucleus and cytoplasm of R6/2 and WT 
mice, respectively (Fig. 1 G). In contrast, AMPK­2 mainly ex­
isted in nuclei of striatal cells of both R6/2 and WT mice (Fig. 1 G), 
further suggesting that AMPK­2 did not contribute to the   
nuclear enrichment of AMPK­­p in the striatum of R6/2 mice. 
Moreover, down­regulation of AMPK­1 using a small hairpin 
RNA (1­shRNA) in STHdh
Q109 cells markedly reduced the 
level of activated AMPK (AMPK­­p; Fig. 2 D), further sup­
porting the idea that AMPK­1 is the major phosphorylated 
AMPK isoform in striatal cells expressing mHtt. These data show 
that the expression of mHtt selectively activates and causes the 
nuclear enrichment of AMPK­1.
Activation of AMPK-1 compromises the 
survival of striatal neurons
The role of AMPK in striatal cells was first examined by a daily 
i.p. injection of 400 mg/kg aminoimidazole carboxamide ribo­
side (AICAR) or vehicle into WT and R6/2 mice for 5 wk from 
the age of 7 wk. A major characteristic of HD is the enlargement 
of the ventricles, which is accompanied by a progressive reduc­
tion in the brain weight. An in vivo 3D magnetic resonance im­
aging (MRI) analysis revealed a higher ventricle to brain ratio 
(VBR) in R6/2 mice than in WT mice (Fig. 3, A and B). A 
histological examination and Nissl staining revealed that the 
2  subunit  is  located  mainly  in  the  nucleus  (Salt  et  al.,  1998;   
Turnley et al., 1999). Localization of AMPK is sensitive to various 
stresses, including heat shock, energy depletion, and oxidants 
(Kodiha et al., 2007). In the nucleus, AMPK phosphorylates 
several transcription factors and cofactors (including FOXO3, 
peroxisome proliferator­activated receptor  coactivator 1 
[PGC­1], p300, and p53] and regulates gene expression (Yang 
et al., 2001; Greer et al., 2007; Jäger et al., 2007; Okoshi et al., 
2008; Chaturvedi et al., 2009). The mechanism responsible for 
the nuclear–cytoplasmic shuttling of AMPK is largely known.
The function and regulation of AMPK and its role in neuro­
degenerative diseases have attracted much attention. For example, 
higher activities of AMPK were found in neurons with ischemia, 
HD, and Alzheimer’s disease (AD; Chou et al., 2005; McCullough 
et  al.,  2005;  Lopez­Lopez  et  al.,  2007).  The  underlying 
mechanisms and consequences of AMPK activation in neu­
rodegenerative disorders remain mostly uncharacterized. The 
substrates of AMPK include proteins involved in energy metabo­
lism and other cellular mechanisms such as apoptosis and cellular 
responses to oxidative stress (Tsuboi et al., 2003; Cai et al., 
2007). We previously demonstrated that AMPK is abnormally 
activated in the striatum of a transgenic mouse model of HD (R6/2; 
Chou et al., 2005). In the present study, we demonstrate that acti­
vation of AMPK­1 in striatal neurons is closely associated with 
mHtt­induced cell death. This AMPK­mediated neurotoxicity 
requires the nuclear translocation of AMPK­1 to suppress the 
expression  of  Bcl2.  Most  importantly,  a  beneficial  reagent 
(CGS21680 [CGS]; Chou et al., 2005) protected striatal cells 
from the mHtt­mediated toxicity via (at least partially) inter­
fering with the detrimental action of AMPK­1.
Results
Selective activation and nuclear enrichment 
of AMPK-1 in striatal neurons of humans 
and mice with HD
To characterize the role of AMPK in HD pathogenesis, we first 
evaluated the activation and subcellular localization of AMPK 
in brains of HD patients using an immunofluorescence stain­
ing technique. Surprisingly, nuclear accumulations of activated 
AMPK (i.e., the AMPK that is phosphorylated at Thr
172, AMPK­
­p) were observed in the caudate nucleus (Fig. 1 A) and frontal 
cortex (Figs. 1 B and S1 A) of both male and female patients 
with HD. In contrast, activated AMPK appeared in the cyto­
plasm of cells in brains of non­HD subjects (Figs. 1 [A and B] 
and S1 [B and C] and Table I). Similar nuclear enrichment of 
AMPK­­p was also observed in the striatum of a transgenic 
mouse model of HD, whereas most AMPK­­p appeared in the 
cytoplasm of striatal cells in wild­type (WT) mice (Fig. 1 C).
stained with Hoechst (blue). The numbers shown in the bottom left corners of the merged images are the percentages of cells expressing nuclear AMPK--p 
or AMPK-1. Thin arrows mark cells containing AMPK, which are located mostly in cytoplasmic regions. Thick arrows mark cells with nuclei enriched with 
AMPK. Values represent the mean ± SEM of at least three independent experiments. At least 200 cells from each sample were analyzed. Bars, 20 µm.   
(E and F) Total striatal lysate of 12-wk-old mice was immunoprecipitated (IP) using the indicated antibody and subjected to Western blot analyses. (G) The 
cytoplasmic (C) and nuclear (N) fractions were harvested from the striatum of 12-wk-old mice and assessed using Western blot analysis. PARP and -tubulin 
were respective markers for the nuclear and cytoplasmic fractions. Data are presented as the mean ± SEM of three independent experiments. Molecular 
mass is indicated in kilodaltons. a, P < 0.05 versus WT cytoplasmic; b, P < 0.05 versus WT nuclear. NRS, normal rabbit serum.
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signals of activated caspases were detected in the striatum of 
R6/2 but not WT mice. Moreover, the number of neurons in 
the striatum of R6/2 mice was significantly reduced by AICAR 
(Fig. 4, C and E). Consistent with the aforementioned detrimen­
tal effect of the intrastriatal infusion of AICAR, stimulation of 
AMPK with AICAR also worsened the rotarod performance 
and reduced the life span of R6/2 mice (Fig. 4, F and G). Col­
lectively, these findings show that AMPK potentiates the striatal 
neurodegeneration triggered by mHtt.
Similar detrimental roles of AMPK were also observed in 
striatal cell lines. We found that the stimulation of AMPK with 
AICAR  caused  dose­dependent  cell  death  in  STHdh
Q7  and 
STHdh
Q109 cells (Fig. 5, A and B). STHdh
Q109 cells, which had 
greater AMPK activity, were more sensitive to AICAR­induced 
cell death than were STHdh
Q7 cells, as assessed by flow cytom­
etry  (Fig.  5  A)  and  the  3­(4,5­dimethylthiazol­2­yl)­2,5­
  diphenyltetrazolium bromide (MTT) reduction assay (Fig. 5 B). 
Moreover, an inhibitor of AMPK, CC, markedly increased cell 
survival after AMPK activation (Fig. 5 C). Consistent with the 
aforementioned observations made in striatal neurons of R6/2 
mice, activated AMPK and AMPK­1 predominantly appeared 
in the cytoplasm and nuclei of STHdh
Q7 and STHdh
Q109 cells, 
respectively (Fig. 5, D and E). Because stimulation of AMPK 
with AICAR significantly enhanced the nuclear localization of 
AMPK­­p and AMPK­1 in striatal cells, whereas blocking 
AMPK  using  CC  eliminated  the  nuclear  accumulation  of 
AMPK­1 in the presence of mHtt (Figs. 4 A, 5 D, and S2),   
we reasoned that activation of AMPK­1 might promote its 
aforementioned brain atrophy observed in 12­wk­old R6/2 mice 
probably resulted from a reduction in the size of the neurons 
(Fig. 3, D and E). Importantly, chronic treatment with AICAR 
further increased the VBR of R6/2 mice (Fig. 3, A and B). Con­
sistent with these findings, AICAR also reduced the brain 
weight of R6/2 mice (Fig. 3 C). The number of neurons in the 
striatum was also markedly lower in AICAR­treated R6/2 mice 
than in control R6/2 mice (Fig. 3, D and F). In both WT and 
R6/2 mice, the level of AMPK­­p was elevated in the striatum 
of mice chronically treated with AICAR (Fig. 3 G). Activation 
of caspase 3 and reduced expression of Bcl2 were also observed 
in the striatum of AICAR­treated mice (Fig. 3, H and I, respec­
tively), suggesting a detrimental effect of activated AMPK on 
the striatum. Filter retardation assays revealed that the activa­
tion of AMPK by AICAR markedly enhanced the formation of 
mHtt aggregates in R6/2 mice (Fig. 3 J). To ensure that the det­
rimental effect of AICAR was caused by direct activation of 
AMPK in the brain, we directly infused AICAR (3 µg/animal/
day; Florant et al., 2010) into the striatum of WT and R6/2 mice 
for 7 d using ALZET osmotic pumps at the age of 12 wk. As ex­
pected, AICAR enhanced the level of AMPK­­p and the nu­
clear localization of AMPK­1 in the striatum of both WT and 
R6/2 mice (Figs. 4 A and S2). Conversely, an AMPK inhibitor, 
compound C (CC), greatly reduced the nuclear localization of 
AMPK­1 in R6/2 mice (Fig. S2). Next, we assessed neuronal 
toxicity using SR­FLIVO, a red fluorescent probe that forms 
covalent bonds with active caspases and therefore detects apop­
totic cells in vivo (Escribano et al., 2009). As shown in Fig. 4 B, 
Table I.  Summary of demographic data, neuropathology, and experimental results of human subjects
Case PMI Brain area Nuclear localization  
of AMPK--p
Nuclear localization  
of AMPK-1
Age Gender HD Vonsattel 
grade
Other pathology
h % % yr
HD-1
a 9 Caudate nucleus 71 ± 5 77 ± 4 80 F I Cortical amyolid plaques
HD-2
a <24 Caudate nucleus 67 ± 7 75 ± 5 70 F IV Brainstem Lewy body
HD-1
a 9 Frontal cortex 67 ± 8 85 ± 4 80 F I Cortical amyolid plaques
HD-2
a <24 Frontal cortex 69 ± 6 70 ± 9 70 F IV Brainstem Lewy body
HD-3
b 15 Frontal cortex 51 ± 8 56 ± 4 57 M I None
HD-4
b 17 Frontal cortex 60 ± 4 64 ± 7 58 M I None
Non–HD-1
a 6 Caudate nucleus 31 ± 7 22 ± 5 93 M n.a. AD break NFT
Non–HD-2
a 14 Caudate nucleus 17 ± 5 20 ± 6 88 F n.a. None
Non–HD-3
a <24 Caudate nucleus 24 ± 6 31 ± 3 82 F n.a. None
Non–HD-4
a 12 Caudate nucleus 25 ± 5 18 ± 5 78 M n.a. AD break NFT
Non–HD-5
a <24 Caudate nucleus 18 ± 4 26 ± 3 74 M n.a. None
Non–HD-6
a <24 Caudate nucleus 21 ± 5 22 ± 3 83 M n.a. None
Non–HD-1
a 6 Frontal cortex 22 ± 5 20 ± 7 93 M n.a. AD break NFT
Non–HD-2
a 14 Frontal cortex 12 ± 4 18 ± 6 88 F n.a. None
Non–HD-3
a <24 Frontal cortex 19 ± 7 22 ± 8 82 F n.a. None
Non–HD-4
a 12 Frontal cortex 27 ± 4 21 ± 5 78 M n.a. AD break NFT
Non–HD-5
a <24 Frontal cortex 25 ± 3 21 ± 7 74 M n.a. None
Non–HD-6
a <24 Frontal cortex 22 ± 5 17 ± 4 83 M n.a. None
Significant amounts of phosphorylated AMPK- at Thr
172 (AMPK--p) and AMPK-1 were found in nuclei in brains of HD patients but not in those of age-matched 
controls. Brain sections were analyzed by immunofluorescence staining of AMPK--p or AMPK-1 as shown in Fig. 1 and Fig. S1. At least 200 cells were counted 
in brain sections of each subject. The Alzheimer-type pathology (both senile plaques and neurofibrillary tangles [NFTs]) was assessed by thioflavin-S fluorescence 
microscopy. The Braak neurofibrillary tangle stage was assigned based on the counts of plaques and neurofibrillary tangles with this method. F, female; M, male; 
n.a., not applicable; PMI, postmortem interval.
aCases obtained from the Mayo Clinic College of Medicine, Rochester, MN.
bCases obtained from the National Institute of Child Health and Development Brain and Tissue Bank for Developmental Disorders at the University of Maryland, 
College Park, MD.213 Functional roles of AMPK in Huntington’s disease • Ju et al.
GFP­positive neurons (Fig. 6 D), suggesting that the nuclear   
localization of AMPK­1 is critical for the degeneration of stria­
tal neurons in the presence of mHtt.
Because Ca
2+ signaling is disrupted in striatal neurons of 
HD mice (Tang et al., 2005) and because Ca
2+/CaM­dependent 
protein kinases (including CaMKK and CaMKII) were re­
ported to be upstream of AMPK (Anderson et al., 2008), we 
evaluated whether CaMKK and CaMKII were involved in the 
activation of AMPK­1 by mHtt. As shown in Fig. 7 A, treat­
ment of STHdh
Q109 cells with an inhibitor (KN62) of CaMKII 
significantly reduced AMPK activation as assessed by the level 
of AMPK­­p. Most importantly, KN62 blocked the nuclear 
enrichment of AMPK­1 (Fig. 7 B). A CaMKK inhibitor 
(STO­609) at up to 10 µM, in contrast, did not prevent the nu­
clear enrichment of AMPK­1 in STHdh
Q109 cells (unpublished 
data). Consistent with the importance of CaMKII in the activa­
tion of AMPK­1 by mHtt, we found that the activity of CaMKII 
in STHdh
Q109 cells was higher than that in STHdh
Q7 cells as   
assessed by the phosphorylation level of CaMKII at Thr
286 
(CaMKII­pT286; Swulius and Waxham, 2008), an autophos­
phorylation site by CaMKII (Fig. 7 C). Similarly, the activity 
of  CaMKII  in  the  striatum  of  R6/2  mice  was  significantly 
higher than that of WT mice (Fig. 7 D). An intrastriatal injec­
tion of KN62 (10 µg per mouse) markedly reduced the level of 
nuclear AMPK­­p  and AMPK­1  in  the  striatum  of  R6/2 
mice (Fig. 7, E–G). Collectively, these findings suggest that the 
dysregulated CaMKII might mediate the abnormal activation 
of AMPK­1 by mHtt.
nuclear translocation. In line with this hypothesis, an exo­
genously  expressed  dominant­positive  AMPK­1  mutant   
(AMPK­1­T172D) was detected consistently in the nuclei of 
STHdh
Q7 cells, whereas a dominant­negative AMPK­1 mutant   
(AMPK­1­T172A)  appeared  in  the  cytoplasm  (Fig.  S3  B). 
Collectively, these results suggest that mHtt causes the phos­
phorylation and activation of AMPK­1, which is then translo­
cated into the nuclei.
To assess whether the nuclear localization of AMPK­1 is 
important, we created AMPK­1 variants to which were fused 
an NLS or a nuclear export signal (NES). The inclusion of an NLS 
or NES restricted the location of the corresponding AMPK­1 
mutant to nuclei or the cytoplasm, respectively (Fig. S3 C). 
The expression of AMPK­1­T172D­NLS, but not AMPK­1­
T172D­NES, significantly caused cell death in STHdh
Q109 cells 
(Fig. 5, F and G). To determine whether nuclear localization of 
AMPK­1 facilitates striatal neurodegeneration in HD, we cre­
ated adeno­associated viruses (AAVs) carrying AMPK­1 vari­
ants fused to the YFP. Fusion of AMPK­1 variants with YFP or 
V5 did not affect their functions or distributions (Fig. S3 A). An 
intrastriatal injection of AAV­AMPK­1­T172D­NLS, but not 
AAV­AMPK­1­T172D­NES or AAV­GFP (a control virus), 
for 5 wk from the age of 7 wk enhanced the number of apoptotic 
cells that contained active caspases in the striatum of R6/2 mice 
compared with those in WT mice (Fig. 6, A and C). We identi­
fied infected striatal cells by the expression of YFP. The number 
of AMPK­1­T172D­NLS–positive neurons in the striatum of 
R6/2 mice was lower than that of AMPK­1­T172D­NES– and 
Figure 2.  Expression of mHtt activates AMPK 
in striatal cells. (A–D) The total lysates were as-
sessed by Western blot analyses. Results were 
normalized to those of actin. (A) Cells were 
incubated with or without 1 mM AICAR for 24 h.   
a,  P  <  0.05  versus  untreated  STHdh
Q7;  b,   
P < 0.05 between cells treated with and with-
out AICAR. (B) ST14 cells were transfected 
with the indicated construct (pcDNA3.1-Htt-[Q]25-
hrGFP,  25Q;  pcDNA3.1-Htt-[Q]109-hrGFP, 
109Q) for 48 h. a, P < 0.05 versus untreated 
25Q  cells.  (C)  Striatal  lysates  of  12-wk-old 
mice were analyzed. a, P < 0.05 versus WT. 
(D) STHdh
Q109 cells were transfected with small 
hairpin RNA of AMPK-1 for 72 h. a, P < 0.05 
versus control STHdh
Q109 cells. Data are pre-
sented as the mean ± SEM of three indepen-
dent experiments. Molecular mass is indicated 
in kilodaltons.JCB • VOLUME 194 • NUMBER 2 • 2011   214
Figure 3.  Activation of AMPK enhances brain atrophy, neuronal loss, and aggregate formation in the striatum of R6/2 mice. (A–J) Mice were treated daily 
with AICAR (400 mg/kg of body weight, i.p.) or saline for 5 wk from the age of 7 wk. (A) Representative 3D brain images from vehicle-treated WT mice 
(n = 6), saline-treated R6/2 mice (n = 6), AICAR-treated WT mice (n = 6), and AICAR-treated R6/2 mice (n = 7). (B and C) The VBR values (B) and brain 
weights (C) are illustrated. a, P < 0.05 between saline-treated WT and R6/2 mice; b, P < 0.05 versus saline-treated mice. (D) Brain sections of 12-wk-old 
mice (saline-treated WT mice [n = 3], saline-treated R6/2 mice [n = 6], AICAR-treated WT mice [n = 5], and AICAR-treated R6/ 2 mice [n = 6]) were 
stained with Nissl stain. Three pictures (marked by pink boxes) were taken from each striatal section and are illustrated on the left. Bars, 25 µm. (E and F) The 
histograms show the striatal neuronal area (E) and the number of striatal neurons (F). a, P < 0.05 between untreated WT and R6/2 mice; b, P < 0.05 versus 215 Functional roles of AMPK in Huntington’s disease • Ju et al.
untreated mice. Nine frames from three brain sections spaced evenly throughout the striatum were analyzed for each animal by an investigator blind to the 
experimental condition. At least 500 and 700 cells from each animal were respectively counted and measured to determine the size of neurons and the 
number of neurons in the striatum. (B, C, E, and F) Data are presented as the mean ± SEM. (G–I) Striatal lysates were analyzed by Western blot analyses. 
Results were normalized to those of actin. a, P < 0.05 between untreated WT and R6/2 mice; b, P < 0.05 versus saline-treated mice. (J) The amount of 
mHtt aggregates in striatal lysates was analyzed by a filter retardation assay. Insoluble aggregates retained on the filters were detected using an anti-Htt 
antibody. a, P < 0.05 versus saline-treated R6/2 mice. (G–J) Data are presented as the mean ± SEM of three independent experiments. Molecular mass 
is indicated in kilodaltons.
 
Figure 4.  Activation of AMPK enhances neuronal loss and motor dysfunction in R6/2 mice. (A–C) 12-wk-old mice were infused with AICAR (3 µg/animal/
day) or saline via osmotic minipumps for 7 d and then subjected to immunohistochemical analyses. Expressions of AMPK--p (A, green), active caspases   
(B, red), and NeuN (C, red) in the striatum of the indicated animals (n = 3–6 for each condition) are shown. Nuclei were stained with Hoechst (A and B, 
blue). The numbers shown in the bottom left corners of the merged images are the percentages of cells expressing nuclear AMPK--p (A).Thin arrows 
mark cells expressing AMPK--p, which is mostly located in cytoplasmic regions. Thick arrows mark cells with nuclei enriched with AMPK--p. Bars, 20 µm. 
(D and E) The histograms show the integrated intensity of active caspases (D) and the number of striatal neurons (E). At least 200 and 1,000 cells from 
each animal were respectively counted and measured to determine the nuclear enrichment of AMPK-p–positive neurons and the number of neurons in the 
striatum, respectively. (F) Rotarod performance (n = 10 for each condition) was determined. (E and F) Data are presented as the mean ± SEM. a, P < 0.05 
between WT and R6/2 mice; b, P < 0.05 versus R6/2-saline mice. (G) Survival was assessed by a Kaplan–Meier survival analysis.JCB • VOLUME 194 • NUMBER 2 • 2011   216
Figure 5.  Expression of mHtt leads to activation and nuclear enrichment of AMPK-1, which plays a detrimental role in striatal cells. (A–C, F, and G) Cells 
were treated with or without the indicated reagents (1 mM AICAR and 10 µM CC) for 24 h. Cell survival was determined by a flow cytometry–based 
analysis (A and G) or MTT reduction assay (B, C, and F). For the MTT assay, values of the indicated cells were normalized to those of untreated or vec-
tor-transfected STHdh
Q7 cells. Data are presented as the mean ± SEM of three independent experiments. (A and B) a, P < 0.05 between STHdh
Q7 and 
STHdh
Q109; b, P < 0.05 versus untreated cells. (C) a, P < 0.05 versus AICAR-treated cells. (D) Immunofluorescence staining of AMPK--p and AMPK-1 was 
conducted. Nuclei were stained with Hoechst (blue). The numbers in the bottom left corners are the percentages of cells expressing nuclear AMPK--p or 
AMPK-1 and were identified by nuclear AMPK--p or AMPK-1 normalized to total AMPK--p or AMPK-1–positive cells. Thin arrows mark cells contain-
ing AMPK, which is located mostly in cytoplasmic regions. Thick arrows mark cells with nuclei enriched with AMPK. Bars, 20 µm. (E) Cytoplasmic and 
nuclear fractions of STHdh
Q7and STHdh
Q109 cells were assessed by Western blot analyses. PARP and -tubulin were respective markers for the nuclear and 
cytoplasmic fractions. Molecular mass is indicated in kilodaltons. a, P < 0.05 versus STHdh
Q7 cytoplasmic fractions; b, P < 0.05 versus STHdh
Q7 nuclear 
fractions. (F and G) Cells were transfected with the indicated construct for 48 h. a, P < 0.05 between STHdh
Q7 and STHdh
Q109 cells; b, P < 0.05 versus 
cells transfected with AMPK-1-T172D-NLS. (D–G) Data are presented as the mean ± SEM of three independent experiments.217 Functional roles of AMPK in Huntington’s disease • Ju et al.
the phosphorylation of CREB in STHdh
Q109 cells. These data 
show that CREB functions downstream of AMPK in striatal 
cells that express mHtt. As expected, stimulation of the A2AR 
with CGS markedly increased the phosphorylation of CREB, 
which was blocked by the PKA inhibitor H89 (Fig. 9 C). 
Most importantly, an inactive CREB mutant (CREB­S133A), 
Nuclear AMPK-1 induces cell death by 
down-regulating Bcl2 in striatal cells
Among the AMPK­regulated survival genes, Bcl2 is implicated 
in the pathogenesis of HD (Zhang et al., 2003). Analyses using 
Western blot assays and a reverse transcription quantitative 
PCR (qPCR) technique showed that levels of the Bcl2 protein 
and Bcl2 transcript in the striatum of R6/2 mice were markedly 
lower than those in WT mice (Fig. 8, A and B). Similarly, levels 
of Bcl2 transcripts and the Bcl2 protein were also lower in the 
STHdh
Q109 cells than in STHdh
Q7 cells (Fig. 8, C and D). Inhibi­
tion of AMPK in STHdh
Q109 cells with an AMPK inhibitor, CC, 
normalized the reduced level of Bcl2 protein, whereas activa­
tion of AMPK by AICAR reduced the level of the Bcl2 protein 
(Fig.  8  D).  Next,  we  transfected  AMPK­1­T172D­NLS, 
AMPK­1­T172D­NES, or AMPK­1­T172A­NLS into STHdh
Q7 
cells and assessed their effects on Bcl2 expression. Only the   
nucleus­restricted positive AMPK­1 mutant (AMPK­1­T172D­
NLS) caused significant reductions in levels of Bcl2 transcript 
and Bcl2 proteins in STHdh
Q7 cells (Fig. 8, E and F). Nuclear 
accumulation  of  AMPK­1  promoted  by  mHtt  thus  causes 
down­regulation of Bcl2. This suppression of Bcl2 is function­
ally important because the overexpression of Bcl2 in STHdh
Q109 
cells enhanced their survival and prevented AICAR­ and nuclear 
AMPK­1–induced cell death (Fig. 8, G–I). Collectively, these 
data suggest that Bcl2 plays a critical role in nuclear AMPK­1–
mediated striatal cell death.
A beneficial reagent (CGS) protects 
striatal cells from mHtt-mediated toxicity 
via interfering with the detrimental action 
of AMPK-1
AMPK was shown to cause cell death by reducing the phos­
phorylation of cAMP response element binding (CREB) at Ser
133 
and Ser
129, thereby inhibiting the CREB­mediated transcription 
of several survival genes (including Bcl2; Horike et al., 2008). 
Because PKA directly phosphorylates CREB at Ser
133, we 
hypothesized that activation of the cAMP–PKA pathway would 
increase the expression of Bcl2 and thus avert the damaging   
effects of AMPK. We previously showed that treatment of R6/2 
mice with an A2AR­selective agonist (CGS) prevented several 
major symptoms of HD (Chou et al., 2005). The major signal 
evoked by activation of the A2AR is the cAMP–PKA pathway 
(Chern et al., 1993). Consistent with our hypothesis, we found 
that the reduction in Bcl2 transcripts in the striatum of R6/2 
mice was rescued by chronic CGS (2.5 mg/kg of body weight) 
treatment (Fig. 9 A). Treating STHdh
Q109 cells with 10 µM CGS 
for 24 h also markedly increased levels of Bcl2 transcripts 
(Fig. 9 B). This enhancing effect of CGS was mediated through 
the A2AR in a PKA­dependent manner because an A2AR­selective 
antagonist (8­[­3­chlorostyryl]­caffeine [CSC]; 20 µM) and a 
PKA inhibitor (H89; 10 µM) suppressed the ameliorating effect 
of CGS on Bcl2 expression (Fig. 9 B). Consistent with the bene­
ficial effects of CGS on R6/2 mice (Chou et al., 2005), CGS 
treatment also enhanced the survival of STHdh
Q109 cells after 
AICAR treatment (Fig. 9, E and F). As shown in Fig. 9 C, the 
level of CREB phosphorylation at Ser
133 was lower in STHdh
Q109 
cells than in STHdh
Q7 cells. The AMPK inhibitor CC increased 
Figure 6.  Nuclear localization of active AMPK-1 causes striatal degenera-
tion in R6/2 mice. (A and B) Mice were intrastriatally injected with an AAV 
carrying a GFP, AMPK-1-T172D-NLS-YFP (DL), or AAV-AMPK-1-T172D-
NES-YFP (DE) at the age of 7 wk. 5 wk after the injection, brain sections 
were harvested and analyzed for neuronal degeneration. (A) Infected cells 
were identified by the expression of AAV-GFP (top, green) or AMPK-1 
mutant–YFP (middle and bottom, green) as indicated. For clarity, examples 
of infected striatal cells of R6/2 mice are marked by white dashed lines and 
are shown at the right. Levels of active caspases (A, red) and NeuN (B, red)   
in the striatum of the indicated mice (n = 3–6 for each condition) are shown. 
Nuclei were stained with Hoechst (A, blue). Thick arrows mark AAV-infected 
cells that were negative for active caspases. Thin arrows mark AAV-infected   
cells that were positive for active caspases. Bars, 20 µm. (C and D) The histo-
grams show the integrated intensity of active caspases (C) and the number of 
striatal neurons (D). Data are presented as the mean ± SEM. At least 1,000 cells 
from each animal were analyzed. a, P < 0.05 between WT and R6/2 mice;   
b, P < 0.05 versus HD-AAV-GFP mice.JCB • VOLUME 194 • NUMBER 2 • 2011   218
in which Ser
133 is converted to Ala (Parker et al., 1996), inhib­
ited the increase in Bcl2 induced by CGS (Fig. 9 B). These 
data show that the phosphorylation of CREB at Ser
133 by PKA 
plays a vital role in A2AR­mediated regulation of Bcl2 in stria­
tal cells.
Consistent with the ability of CGS to increase the phos­
phorylation of CREB (Fig. 9 C), CGS also effectively protected 
STHdh
Q109 cells from cell death (Fig. 9, D–F). Down­regulation 
of AMPK­1 using small hairpin RNA elevated the survival of 
STHdh
Q109 cells to a similar level as that of STHdh
Q7 cells and 
blunted the effect of CGS (Fig. 9 D). Similarly, an antagonist of 
the A2AR (CSC), a PKA inhibitor (H89), and a dominant­negative 
mutant of CREB (CREB­S133A) blocked the ameliorating   
effects of CGS (Fig. 9, E and F), which supports the notion that 
Figure 7.  Expression of mHtt causes the activation and nuclear enrichment of AMPK-1 through a CaMKII-mediated pathway. (A) Total lysates of STHdh
Q7 
and STHdh
Q109 cells were assessed by Western blot analyses. Results were normalized to those of actin. a, P < 0.05 versus untreated STHdh
Q109 cells. 
(B) Cytosolic and nuclear fractions were harvested from STHdh
Q7and STHdh
Q109 cells and assessed by Western blot analyses. PARP and -tubulin were 
markers for the nuclear and cytoplasmic fractions, respectively. a, P < 0.05 versus untreated STHdh
Q7 cells; b, P < 0.05 versus untreated STHdh
Q109 cells. 
(C) Total lysates of STHdh
Q7 and STHdh
Q109 cells were assessed by Western blot analyses. Results were normalized to those of actin. a, P < 0.05 versus 
untreated STHdh
Q7 cells. Molecular mass is indicated in kilodaltons. (D) Total striatal lysates of 12-wk-old mice were assayed for CaMKII activity. Values 
are expressed as percentages of the CaMKII activity in WT mice. a, P < 0.05 between WT and R6/2 mice. (A–D) Data are presented as the mean ± SEM 
of three independent experiments. (E and G) 10-wk-old mice (n = 3–6 for each condition) were intrastriatally injected with KN62 (10 µg per mouse) or 
saline. 1 d after injection, brain sections were harvested to analyze the expressions of AMPK--p (E, green) and AMPK-1 (G, green). Nuclei were stained 
with Hoechst (blue). The numbers shown in the bottom left corners of the merged images are the percentages of cells expressing nuclear AMPK--p (E) or 
AMPK-1 (G) and were identified by nuclear AMPK--p (E) or AMPK-1 (G) normalized to total AMPK--p or AMPK-1–positive cells. Data are presented 
as the mean ± SEM. At least 200 cells from each animal were analyzed. Thin arrows mark cells in which AMPK--p is located mostly in the cytoplasmic 
region. Thick arrows mark cells with nuclear enrichment of AMPK--p. Bars, 20 µm. (F) The histogram shows the fluorescence intensity of AMPK--p (n = 6 
for each condition). Data are presented as the mean ± SEM. a, P < 0.05 between WT and R6/2 mice; b, P < 0.05 versus R6/2-saline mice.219 Functional roles of AMPK in Huntington’s disease • Ju et al.
Figure 8.  Nuclear enrichment and activation of AMPK-1 mediate the suppression of Bcl2 by mHtt. (A, C, and E) Total RNA was harvested from the 
striatum of 12-wk-old mice (A) and striatal cell lines (C and E) to analyze transcript levels of Bcl2 using reverse transcription qPCR. Transcript levels of Bcl2 
were normalized to those of GAPDH. a, P < 0.05. (B, D, and F) Total protein lysates were prepared from the striatum of 12-wk-old mice (B) and striatal 
cell lines (D and F) for Western blot analyses to determine protein levels of Bcl2. Protein levels of Bcl2 were normalized to that of actin. Molecular mass   
is indicated in kilodaltons. (D) Cells treated with 1 mM AICAR and 10 µM CC as indicated for 24 h. a, P < 0.05 versus untreated STHdh
Q7 cells; b,   
P < 0.05 versus untreated cells. (E and F) STHdh
Q7 cells were transfected with the indicated construct and then incubated for 48 h. a, P < 0.05 versus cells 
transfected with the empty vector (pcDNA3.1); b, P < 0.05 versus cells transfected with AMPK-1-T172D-NLS. (G and H) Cells were transfected with an 
empty vector (pcDNA3.1) or an expression construct of Bcl2 for 24 h followed by a 24-h incubation with 1 mM AICAR. Cell survival was determined by 
an MTT assay (G) and a flow cytometry–based analysis (H). a, P < 0.05 between STHdh
Q7 and STHdh
Q109 cells; b, P < 0.05 versus AICAR-treated vector-
expressing cells. (I) STHdh
Q109 cells were transfected with the indicated constructs for 48 h. Cell survival was determined by an MTT assay. a, P < 0.05 
between STHdh
Q7 and STHdh
Q109 cells; b, P < 0.05 versus cells transfected with AMPK-1-T172D. (A–I) Data are presented as the mean ± SEM of three 
independent experiments. (J) Immunofluorescence staining of Bcl2 (top and middle, short exposure; bottom, long exposure) and a mitochondrial marker 
(succinate dehydrogenase [SDHA]) in STHdh
Q7 and STHdh
Q109 cells was conducted as indicated. Nuclei were stained with Hoechst (blue). Bar, 20 µm.JCB • VOLUME 194 • NUMBER 2 • 2011   220
that the effects of CGS are mediated through the A2AR and PKA 
(Fig. 9 H). The direct activation of adenylyl cyclases with for­
skolin also inhibited AMPK phosphorylation during AICAR 
treatment (Fig. 9 I). PKA thus mediates the rescue effect of the 
A2AR on the detrimental role of AMPK­1 in striatal neurons. 
CGS treatment at an earlier time point (6 h) also effectively 
activation of the A2AR rescues the AMPK­mediated detrimental 
effects via the PKA–CREB pathway.
Next, we showed that CGS treatment suppressed AMPK 
phosphorylation/activation (Fig. 9 G). The suppressive effect of 
CGS on AMPK activation was reduced by an A2A antagonist 
(CSC) and two PKA inhibitors (H89 and KT5720), indicating 
Figure 9.  Stimulation of the A2AR rescued AMPK-mediated suppression of Bcl2 via a PKA–CREB-dependent pathway. (A) Mice were treated daily with CGS 
(2.5 mg/kg of body weight, i.p.) or vehicle for 6 wk from the age of 4 wk. Transcript levels of Bcl2 assessed by reverse transcription qPCR were normalized 
to those of GAPDH. a, P < 0.05 versus R6/2 mice. (B and D–F) Cells were transfected with the indicated constructs for 24–48 h and then treated with the 
indicated reagents for 24 h. Transcript levels of Bcl2 assessed by reverse transcription qPCR were normalized to those of GAPDH (B). a, P < 0.05 versus 
untreated STHdh
Q7 cells; b, P < 0.05 versus STHdh
Q109 cells treated with CGS; c, P < 0.05 with a specific comparison between cells transfected with CREB-
WT and CREB-T133A; d, P < 0.05 versus untreated STHdh
Q109 cells; e, P < 0.05 versus AICAR-treated cells. (D–F) Cell survival was determined using an 
MTT assay (D and E) and flow cytometry–based analysis (F). (C and G–I) Cells were treated with the indicated reagents for 24 h. Levels of phosphorylated 
CREB (CREB-p
S133) were assessed by Western blot analyses and normalized to those of total CREB (C). Levels of AMPK--p
T172 and AMPK-1 were assessed 
by Western blot analyses and normalized to those of actin (G–I). Molecular mass is indicated in kilodaltons. a, P < 0.05 versus untreated STHdh
Q109 cells; 
b, P < 0.05 versus untreated STHdh
Q7 cells. (A–I) Data are presented as the mean ± SEM of three independent experiments.221 Functional roles of AMPK in Huntington’s disease • Ju et al.
suppressed activation of AMPK, retained AMPK­1 in the cyto­
plasm, and reversed the lower phosphorylation level of CREB 
in STHdh
Q109 (Fig. 10, A–C). Together with observations that 
CGS treatment protected striatal cells (Fig. 9, D–F), this finding 
supports our hypothesis that prevention of the nuclear accumu­
lation of AMPK­1 is beneficial to striatal cells.
Discussion
In this study, we demonstrated that mHtt activates AMPK­1 
and translocates it into the nuclei of two striatal cell lines that 
express mHtt and into nuclei of striatal neurons in mice and   
humans with HD (Figs. 1 and S1 and Table I). The observation that 
Figure 10.  Activation of the A2AR using CGS inhibits the translocation of AMPK-1 into nuclei of STHdh
Q109 cells. (A–D) Cells were treated with or without 
the indicated reagents (10 µM CC, 10 µM CGS, 10 µM H89, 20 µM CSC, and/or 1 mM AICAR) for 6 h. (A) Immunofluorescence staining of AMPK-1 
was conducted. Nuclei were stained with Hoechst. Thin arrows mark cells in which AMPK-1 is located mostly in the cytoplasmic region. Thick arrows 
mark cells with nuclear enrichment of AMPK-1. Bar, 20 µm. (B) Total lysates were analyzed for Western blot analyses. Results were normalized to actin.   
(C) Levels of phosphorylated CREB (CREB-p
S133) were assessed by Western blot analyses and normalized to those of total CREB. (B and C) Data are presented 
as the mean ± SEM of three independent experiments. Molecular mass is indicated in kilodaltons. a, P < 0.05 versus untreated STHdh
Q109 cells. (D) A 
schematic representation of signaling pathways that mediate the action of A2AR in rescuing the detrimental effect of AMPK-1 via a PKA–CREB-dependent 
pathway in the presence of mHtt. The gray circle and orange circle represent the soma and nucleus of striatal neurons, respectively.JCB • VOLUME 194 • NUMBER 2 • 2011   222
increased nuclear accumulation of AMPK­1 was found in   
two affected brain areas of HD patients (Figs. 1 [A and B] and 
S1 [A–C]) demonstrates the clinical relevance of this finding. 
Expression of polyQ­expanded mHtt appeared to enhance the 
activity of CaMKII and subsequently activated and promoted 
the nuclear enrichment of AMPK­1 (Fig. 7). Such nuclear en­
richment of activated AMPK­1 caused a reduction in the ex­
pression of Bcl2 in a CREB­dependent manner and promoted 
cell death. A beneficial reagent, CGS, activated the cAMP–PKA 
pathway and protected striatal neurons by attenuating the detri­
mental role of AMPK­1 via at least two independent routes. 
First, PKA phosphorylated CREB at Ser
133 and consequently 
increased the expression of Bcl2. Second, PKA suppressed the 
activity of AMPK, which in turn prevented the nuclear translo­
cation  of AMPK­1  and  the  subsequent  down­regulation  of 
Bcl2 expression (Fig. 10 D). Our findings provide insights into 
a novel mechanism by which energy deficiency significantly 
contributes to HD pathogenesis and shed new light on the pro­
tective effects of cAMP­elevating reagents in a mouse model of 
HD (Chou et al., 2005; Giampà et al., 2009).
The role of AMPK activation in HD pathogenesis appears 
highly complex. An earlier study showed that a 5­wk treatment 
with metformin extends the shortened life span and reduces the 
hind limb clasping of male R6/2 mice (Ma et al., 2007). Except 
for  the  validation  of AMPK  activation  in  the  striatum  using 
Western blot analyses, no histological examination of brains of 
metformin­treated HD mice was conducted. These authors con­
cluded that the site of metformin’s action remains unclear and 
that  the  improvement  in  the  functions  of  peripheral  systems 
might contribute to this metformin­mediated beneficial effect 
(Ma et al., 2007). To assess the pathological role of AMPK­1 in 
striatal neurons during HD progression, we used multiple ap­
proaches to evaluate the brains of HD mice treated with AICAR 
or AMPK mutants in the present study. It is important to note 
that besides activating AMPK, AICAR also has other effects.   
For example, AICAR induces astroglial differentiation of neural 
stem cells via activating an AMPK­independent and JNK–
STAT3­mediated pathway (Zang et al., 2008). Nonetheless, the 
harmful role of AMPK­1 in striatal cells expressing mHtt was 
clearly validated using both pharmacological (AICAR and CC) 
and genetic tools (dominant­positive or ­negative mutants and 
siRNA of AMPK­1). Data from 3D MRI, brain weights, histo­
logical examinations, behavioral changes, and expression pro­
files of apoptosis/survival signals consistently showed that 
activation of AMPK­1 in striatal neurons potentiates striatal 
atrophy,  neuronal  loss,  and  motor  dysfunction  evoked  by 
mHtt (Figs. 3, 4, and 6). Given that mHtt selectively activates 
AMPK­1 in the striatum of HD animals (Fig. 1, E and F) and 
that the heterotrimeric subunit compositions of AMPK in the 
brain and peripheral tissues (e.g., the muscles) might greatly differ 
(Stapleton et al., 1996; Wojtaszewski et al., 2005), modula­
tion of AMPK­mediated pathways by mHtt might differ in 
different tissues. Further studies are required to delineate the 
tissue­specific regulation of AMPK and its pathogenic conse­
quences during the progression of HD.
In addition to its role in peripheral metabolic diseases   
(e.g., diabetes and cardiac ischemia), AMPK has also attracted 
much  attention  lately  in  the  context  of  neurodegenerative 
diseases.  Specifically, AMPK­  is  highly  enriched  in  pri­
mary cortical and hippocampal neurons under ischemic stress   
(McCullough et al., 2005) and in a transgenic model of AD   
(Lopez­Lopez et al., 2007). Numerous studies showed that AMPK 
plays a proapoptotic role in various cell types, such as cortical 
neurons, hepatocytes, neuroblastoma cells, and mouse insulin­
oma 6 cells (Meisse et al., 2002; Garcia­Gil et al., 2003; Kefas 
et al., 2003; Jung et al., 2004). Besides modulating Bcl2 expres­
sion, activation of AMPK by isotope­coded affinity tag may 
also alter the activity of other prosurvival genes/proteins in HD. 
Using Western blot analyses, we found that the activities of two 
prosurvival proteins (ERK1/2 and Akt) were lower in the stria­
tum of 12­wk­old R6/2 mice than those of WT mice (unpub­
lished data). A daily i.p. injection of AICAR (400 mg/kg of 
body weight) for 5 wk further reduced the phosphorylation/ac­
tivation of ERK1/2 in the striatum of R6/2 mice by 20 ± 5% 
(mean ± SEM, P < 0.05, three independent experiments, Stu­
dent’s t test). Mild suppression of ERK1/2 therefore might also 
contribute to AMPK­1–evoked toxicity in striatal cells. In 
contrast, the same AICAR treatment did not affect the phos­
phorylation/activation of Akt (unpublished data). It remains to 
be determined whether the AICAR­mediated effect on the phos­
phorylation/activation of ERK1/2 is direct or indirect. Given the 
therapeutic potential of prosurvival genes/proteins in HD, fu­
ture studies are warranted to investigate the complex regulation 
of these prosurvival signals by AMPK during HD progression.
Given the key regulatory role of AMPK in energy homeo­
stasis, AMPK is believed to fine tune survival and cell death 
upon being stressed via modulating multiple cellular machiner­
ies. In contrast to the detrimental role of AMPK­1 in HD as 
shown in the present study, protective roles of AMPK were also 
reported in several different cell types (Shaw et al., 2007). For 
example, AMPK activation mediates autophagy­enhanced sur­
vival during oxidative stress or treatment with anticancer drugs. 
Several downstream targets of AMPK are also known to play 
protective roles against stress under defined conditions and in 
specific tissues. Among them, PGC­1 is of particular interest. 
PGC­1 is a transcription factor important in many metabolic 
pathways and is known to play a protective role in HD (Cui   
et al., 2006). In muscles of WT mice, activation of AMPK directly 
phosphorylates and activates PGC­1 and enhances mitochon­
drial biogenesis (Jäger et al., 2007; Chaturvedi et al., 2009). 
However, the activity of AMPK is not elevated by mHtt in mus­
cles  of  NLS­N171­82Q  mice  (a  transgenic  mouse  model  of 
HD), nor does energy depletion activate AMPK or PGC­1 in 
muscles of HD mice, demonstrating an impaired AMPK path­
way in the muscles of HD animals (Chaturvedi et al., 2009). 
The role of AMPK activation in regulating PGC­1 in the brains 
of mice or humans with HD is currently unknown and warrants 
further investigation.
Our finding that mHtt selectively activates AMPK­1 
but not AMPK­2 is intriguing. Such selective regulation of 
the AMPK  isoform  in  other  pathophysiological  conditions 
was previously reported. Specifically, acute exercise in pa­
tients with type 2 diabetes or depletion of phosphocreatine in 
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AD pathogenesis. Caution might be exercised when prescribing 
general AMPK activators for diabetic patients who also exhibit 
symptoms of neurodegenerative diseases with elevated AMPK 
activity in the brain (Chou et al., 2005; McCullough et al., 2005; 
Lopez­Lopez et al., 2007). Given the potential isoform­specific 
functions and regulation of the AMPK isoform as shown in the 
present study and in other studies (Fujii et al., 2000; Musi et al., 
2001), development of isoform­specific AMPK activators and 
inhibitors will be of value for future clinical applications.
Materials and methods
Cell cultures
Striatal progenitor ST14A, STHdh
Q7, and STHdh
Q109 cell lines were gifts 
from E. Cattaneo and M. Valenza (University of Milano, Milano, Italy). 
These cells were maintained in an incubation chamber gassed with 5% 
CO2-95% air at 33°C (Cattaneo and Conti, 1998). Cells were transfected 
using Lipofectamine 2000 (Invitrogen) following the manufacturer’s proto-
col and were cultured for another 48 h in the presence or absence of the 
indicated reagents.
Constructs
The pcDNA3.1-Htt-(Q)25-hrGFP and pcDNA3.1-Htt-(Q)109-hrGFP constructs 
encoding  an  N-terminal  fragment  of  Htt  with  the  indicated  number  of 
polyQ residues fused to a gene encoding hrGFP were created as previ-
ously described (Chiang et al., 2005). Mouse AMPK-1 cDNA was ampli-
fied  from  mouse  brain  cDNA  and  subcloned  into  the  BamHI  site  of 
pcDNA3.1 (Invitrogen). The dominant-positive mutant of AMPK-1 (AMPK-1-
T172D) and the dominant-negative mutant of AMPK-1 (AMPK-1-T172A) 
were created by mutating the Thr
172 residue into Asx and Ala, respectively 
(Stein  et  al.,  2000).  AMPK-1-T172D-NLS/NES  and  AMPK-1-T172A-
NLS/NES were created by fusing the corresponding AMPK-1 variant to 
an NLS (PKKKRKV) or an NES (LPPLERLTLDS; Cong and Varmus, 2004). 
The NES and NLS constructs were gifts from W.-Y. Tarn (Institute of Biomedi-
cal Sciences, Academia Sinica, Taipei, Taiwan). The CREB constructs were 
a gift from H.-M. Shih (Institute of Biomedical Sciences, Academia Sinica, 
Taipei, Taiwan).
Construction, production, and intrastriatal injection of adeno-associated 
viral vectors
Pseudotyped AAV8 vectors were generated by transient transfection of 
HEK293 cells with the target plasmid along with helper plasmids as de-
tailed in Xiao et al. (1998). The DNA fragment that encodes NLS-EYFP-
AMPK-1 or NES-EYFP-AMPK-1 was created by fusing an NLS (PKKKRKV) 
or an NES (LPPLERLTLDS) to EYFP-AMPK-1 by a PCR-based molecular biol-
ogy technique, and this was subcloned into the NotI site of the AAV8 virus 
construct (pXX-UF1-CB; Pan et al., 2008). The physical vector titers of AAVs 
were assessed by determining the number of packaged vector genomes 
using a qPCR method as described in C.C. Chen et al. (2009). Titers of 
AAV-GFP,  NLS-EYFP-AMPK-1,  and  NES-EYFP-AMPK-1  were  10
11/µl,   
1.6 × 10
11/µl, and 1.8 × 10
11/µl, respectively.
For the in vivo expression of AMPK-1, male mice were anesthe-
tized with ketamine/xylazine (100 and 16 mg/kg i.p., respectively;   
Merial Laboratoire de Toulouse) and intrastriatally injected with the indicated 
AAV vector (1–2 µl) through a 10-µl syringe (Hamilton) fitted with a   
26-gauge beveled hypodermic needle for 10 min at a rate of 200 nl/min. 
The anterior–posterior and medial–lateral coordinates were 0.5 and ±2 
mm relative to the bregma, respectively. The dorsoventral coordinates were 
3, 2.7, and 2.4 mm relative to the bregma.
Animals and AICAR administration
R6/2 mice (Mangiarini et al., 1996) were originally obtained from The 
Jackson Laboratory and were mated to female control mice (B6CBAFI/J). 
Offspring were identified by the PCR genotyping and sequencing technique 
of genomic DNA using primers located in the transgene (5-CCGCTCAG-
GTTCTGCTTTTA-3 and 5-GGCTGAGGAAGCTGAGGAG-3). The num-
ber of CAG repeats of R6/2 mice used in this study was 212 ± 9. In total, 
428 R6/2 transgenic mice and 321 WT littermate controls were used in the 
present study. Animals were housed at the Institute of Biomedical Sciences 
Animal Care Facility under a 12-h light/dark cycle. Animal experiments 
were performed under protocols approved by the Academia Sinica Institu-
tional Animal Care and Utilization Committee. For in vivo AMPK activation 
not AMPK­1 in the muscles (Fujii et al., 2000; Musi et al., 
2001).  It  was  hypothesized  that AMPK­1  and AMPK­2 
might have different substrate specificities and play distinct 
physiological roles in human skeletal muscles (Weekes et al., 
1993; Fujii et al., 2000). However, no significant difference 
between the catalytic activities of AMPK­1 and AMPK­2 
was found when assessed using an artificial substrate (Woods 
et  al.,  1996).  Further  investigation  is  needed  to  determine 
whether the  and  subunits of AMPK determine the sub­
strate specificity by targeting specific binding proteins under 
various pathophysiological conditions.
To assess whether the activation and nuclear accumulation 
of AMPK­1 in the brain is a common pathogenesis of polyQ 
diseases, we transfected ST14A cells with the expression con­
struct of spinocerebellar ataxia type 3 (SCA3; Chai et al., 1999), 
which harbors a normal (28) or an expanded (84) number of 
CAG repeats and was fused to hrGFP. As expected, expression 
of SCA3­84Q:hrGFP, but not SCA3­28Q:hrGFP, formed aggre­
gates (Fig. S4 A). However, the expression of neither SCA3­
84Q:hrGFP nor SCA3­28Q:hrGFP triggered activation and/or 
nuclear enrichment of AMPK (Fig. S4 B), suggesting that regu­
lation of AMPK­1 in the brain of HD is mHtt specific. The 
molecular mechanism underlying the nucleocytoplasmic shut­
tling of AMPK­1 in striatal neurons that express mHtt is 
currently unknown. The ERK1/2 pathway might warrant inves­
tigation because a previous study suggested that it controls the 
cellular localization of AMPK in HeLa cells under stressful 
conditions  (Kodiha  et  al.,  2007). Although  we  cannot  com­
pletely exclude the possibility, it is unlikely that mHtt directly 
binds with AMPK­1 and thus leads to nuclear enrichment of 
AMPK­1 because we failed to coimmunoprecipitate AMPK­1 
with mHtt in an attempt to detect a direct interaction between 
AMPK­1 and mHtt (Fig. S5, A and B). Moreover, neither 
AMPK­1 nor AMPK­2 was detected in aggregates of mHtt 
in the striatum of R6/2 mice as assessed by a filter retardation 
assay (Fig. S5 C), suggesting that AMPK might not interact 
with mHtt and form aggregates. Another component that was 
implicated in cellular localization and nuclear redistribution of 
AMPK is its 1 subunit (Warden et al., 2001; Hedbacker and 
Carlson, 2006). We thus examined the subcellular localization 
and phosphorylation level of AMPK­1 in striatal cells ex­
pressing mHtt and found no difference between STHdh
Q7 and 
STHdh
Q109 cells (Fig. S5, D and E). The exact molecule that 
mediates the activity­dependent nuclear enrichment of AMPK­1 
remains to be identified in the future.
It will be of interest to examine whether the nuclear trans­
location  of AMPK­1  contributes  to  the  pathogenic  mecha­
nisms of other brain diseases and traumas in which AMPK 
overactivation was reported (McCullough et al., 2005; Lopez­
Lopez et al., 2007). Y. Chen et al. (2009) earlier demonstrated 
that metformin enhances the biogenesis of amyloid peptides, 
which is mediated by transcriptional up­regulation of ­secretase 
(BACE1) in an AMPK­dependent pathway and which might 
worsen the progression of AD. Because the transcriptional 
regulation of BACE1 by AMPK might occur in the nucleus, 
it will be important to identify the subcellular localization 
and the identity of the AMPK­ isoform that is involved in   JCB • VOLUME 194 • NUMBER 2 • 2011   224
CaMKII activity assay
Total striatal lysate of three animals from each group of 12-wk-old R6/2 or 
WT mice was harvested for the CaMKII assay using the SignaTECT CaM 
kinase II Assay System (Promega). Tissues were homogenized in cold lysis 
buffer (20 mM Tris-HCl, pH 8.0, 2 mM EDTA and EGTA, 100 nM okadaic 
acid, 2 mM DTT, 1 mM PMSF, a protease inhibitor cocktail, and a phos-
phorylation  inhibitor  cocktail).  The  homogenates  were  centrifuged  at 
12,000 g for 20 min at 4°C. Samples were incubated at 30°C for 3 min, 
and the reaction was terminated by adding termination buffer (7.5 M gua-
nidine hydrochloride). The 10-µl reaction mixtures were then spotted onto 
a  prenumbered  square  of  the  SAM  Membrane  (Promega),  which  was 
washed and dried according to the manufacturer’s protocol. The amount of 
-[
32P]ATP incorporated into the CaMKII substrate was visualized by a 
PhosphorImager (Bio-Rad Laboratories). Data are presented as the percent-
age of activity with respect to WT mice.
Cell death assays
Cell death was quantified by an MTT reduction assay and a flow cytometric 
analysis. The MTT reduction assay was conducted as described in Ju et al. 
(2005). In brief, MTT was dissolved in 50 mg/ml DMSO as a 100-fold 
stock solution. At the end of the experiments, cells were incubated in culture 
medium with 0.5 mg/ml MTT at 33°C for 2 h. The culture medium was then 
replaced with DMSO (100 µl in 96-well plates) to dissolve the MTT forma-
zan precipitates, and the absorbance was measured at a wavelength of 
570 nm in a microplate reader (OPTImax tunable plate reader; Molecular 
Devices). The flow cytometric analysis of apoptosis was conducted by stain-
ing the cells with propidium iodide and sorting them with a flow cytometer 
as previously described (Nicoletti et al., 1991). In brief, after drug treat-
ment, cells were rinsed with ice-cold PBS, fixed with 70% ethanol at 20°C 
for 1 h, and centrifuged at 500 g for 5 min at 4°C. After removal of the su-
pernatant, the cell pellet was resuspended in 1 ml PBS containing 50 µg/ml 
propidium iodide plus 20 µg/ml RNase A, incubated in a 37°C water bath 
with gentle shaking in the dark, and filtered through a 70-µm nylon mesh to 
remove clumps. Apoptosis was analyzed using a flow cytometer (BD). The 
sub-G1 fraction was quantified and designated the apoptotic portion. Data 
were analyzed with CellQuest software (BD). At least 10
4 gated cells were 
counted for each sample. The percentage of cells in the sub-G1 phase of the 
cell cycle was estimated according to the DNA content.
SDS-PAGE and Western blotting
A Western blot analysis was performed as previously described (Chiang 
et  al.,  2007).  In  brief,  proteins  were  electrophoretically  fractionated 
through an 8 or 10% SDS polyacrylamide gel and electrotransferred 
onto polyvinylidene difluoride membranes (Millipore). The following pri-
mary antibodies were applied to the blots at the indicated dilutions: anti–
AMPK--p
T172  (1:1,000;  Cell  Signaling  Technology),  anti–AMPK-1 
(1:1,000;  Abcam),  anti–AMPK-2  (1:1,000;  Abcam),  anti–ERK1/2-p 
and anti-ERK1/2 (1:1,000; Cell Signaling Technology), anti–Akt-p and 
anti-Akt (1:1,000; Santa Cruz Biotechnology, Inc.), antitubulin (1:2,000; 
Sigma-Aldrich), anti–poly (ADP-ribose) polymerase (PARP; 1:2,000; Mil-
lipore),  anti-EM48  (Millipore),  anti-V5  (1:  2,000;  Millipore),  antiactin 
(1:5,000; Santa Cruz Biotechnology, Inc.), anti-Bcl2 (1:1,000; Cell Sig-
naling  Technology),  anti–procaspase  3,  and  anti–active  caspase  3 
(1:1,000; Cell Signaling Technology). The immunoreactive signals were 
detected with ECL reagents (PerkinElmer).
Filter retardation assay
SDS-insoluble mHtt aggregates were quantified as previously described 
(Chiang et al., 2007). In brief, brain tissues were suspended and homoge-
nized in ice-cold radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-
HCl, 0.25% sodium deoxycholate, 1% Triton X-100, 150 mM NaCl, 1 mM 
PMSF, 1 mM Na3VO4, 0.5 mg/ml aprotinin, 0.1 mM leupeptin, and 4 mM 
pepstatin), mixed with 2% SDS, and applied to OE66 membrane filters 
(0.2-mm pore size; GE Healthcare) through a slot-blot manifold (Bio-
Rad Laboratories). The blots were blocked with 5% skim milk in PBS and in-
cubated  overnight  with  an  anti-Htt  antibody  (1:500;  Millipore)  at  4°C 
followed by incubation with the corresponding secondary antibody for 1 h 
at RT. The immunoreactive bands were detected by ECL (Thermo Fisher Sci-
entific) and recorded using XAR-5 film (Kodak).
RNA purification and real-time qPCR
RNA purification and cDNA synthesis were performed using TRIZOL re-
agent (Invitrogen) and SuperScript II (Invitrogen), respectively, following the 
manufacturers’ protocols. The qPCR was performed using the LightCycler 
FastStart DNA Master
PLUS SYBR green I kit with a LightCycler (Roche). PCRs 
were performed under the following conditions: 95°C for 10 min followed 
by AICAR, male mice were subcutaneously implanted with ALZET osmotic 
minipumps, which delivered AICAR (3 µg/animal/day) or saline into the 
striatum for 7 d. The anterior–posterior and medial–lateral coordinates were 
0.5 and ±2 mm relative to the bregma, respectively. The dorsoventral co-
ordinates were 3, 2.7, and 2.4 mm relative to the bregma.
Rotarod performance
Motor coordination was assessed using a rotarod apparatus assay (model 
7600; Ugo Basile) at a constant speed of 12 rpm over a period of 2 min. 
All mice were tested three times per week. For each test, animals were 
placed in the apparatus before the initiation of rotation. Each mouse was 
given three trials for a maximum of 2 min for each trial.
Micro-MRI analysis
Whole-brain and 3D ventricle images of the animals were evaluated using 
a PharmaScan scanner (7 T; Bruker) as previously described (Chou et al., 
2005), with modifications. Specifically, sagittal T2-weighted rapid-acquisition 
relaxation-enhanced images (with a repetition time of 2,000 ms, an ef-
fective echo time of 88.3 ms, a field of view of 3 cm, and a matrix of   
256 × 128) were acquired and used to determine the location and length of 
the brain. T2-weighted 3D rapid-acquisition relaxation-enhanced scans were 
acquired axially (with a repetition time of 4,000 ms, an effective echo time 
of 80 ms, a voxel size of 5.71 × 10
6 cm, and a matrix of 256 × 128 × 32). 
The VBR was measured by in vivo 3D MRI and calculated by dividing the 
value of the ventricle by that of the entire brain.
Immunohistochemistry and quantitation
Mice were anesthetized with an i.p. injection of 80 mg/kg sodium pento-
barbital before intracardial perfusion with 4% PFA in 0.1 M phosphate 
buffer (PB; pH 7.4). After perfusion, the brains were carefully removed, 
fixed for 24 h in the same solution, immersed in 30% sucrose in 0.1 M PB 
for 2 d, and frozen on dry ice. Coronal serial sections were cut at 20 µm 
(HM430; Thermo Fisher Scientific) and stored in 6-well plates. Brain sec-
tions  were  immunohistochemically  stained  as  previously  described  (Liu   
et al., 1998). In brief, brain sections were incubated overnight with the ap-
propriate primary antibody in PBS containing 5% normal goat serum at 
4°C and then incubated with the corresponding secondary antibody for   
2 h at RT. The following primary antibodies were applied at the indicated 
dilutions in blocking buffer: anti-phospho–AMPK- (1:100), anti–AMPK-1 
(1:200), anti–neuronal nuclei (NeuN; 1:1,000; Millipore), and anti-V5 
(1:250). Nuclei were stained with Hoechst 33258. Slides were mounted 
using Vectashield (Vector Laboratories). Patterns of immunostaining were 
analyzed with a laser confocal microscope (LSM510; Carl Zeiss). Those 
containing the striatum (interaural 4.66 mm/bregma 0.86 mm to inter-
aural 4.18 mm/bregma 0.38 mm) were stained for Nissl substance using 
cresyl violet or NeuN as previously described (Lee et al., 2009). In Nissl-
stained brain sections, neurons appeared round and light purple. Unless 
otherwise stated, three pictures (marked by pink boxes) were taken of each 
striatal section as illustrated (Fig. 3 D, left) using a camera (Coolpix 5000; 
Nikon). Nine frames from three sections spaced evenly throughout the stria-
tum (interaural 5.34 mm/bregma 1.54 mm to interaural 3.7 mm/bregma 
0.1 mm) were analyzed for each animal by an investigator blind to the 
experimental condition. At least 500 and 700 cells from each animal were 
counted and measured to determine the size and number of neurons in the 
striatum, respectively. Neurons and signals of active caspases within count-
ing frames of 266 × 200 µm were analyzed using 40× 1.0 or 2.0 NA or 
63×  1.0  NA  oil  objective  lenses  (Nikon).  Images  were  imported  into   
ImageJ software (National Institutes of Health). To estimate the neuronal area, 
we outlined each neuronal soma at the plane of its nucleolus and measured 
the cross-sectional area using the ImageJ software as previously described 
(Chou et al., 2008). Quantitation of active caspases was conducted by   
laser confocal microscopy (LSM780; Carl Zeiss) and analyzed with the 
MetaMorph imaging system (Universal Imaging). The fluorochromes used 
in the present study were DAPI and Alexa Fluor 488, 568, and 633.
In vivo cell death assay
The SR-FLIVO in vivo apoptosis assay kit (ImmunoChemistry Technologies, 
LLC) was used to label apoptotic cells in vivo (Riol-Blanco et al., 2009).   
SR-FLIVO prepared as described in the manufacturer’s manual was intrave-
nously injected into the lateral tail vein of each mouse and was allowed to 
circulate in the body for 60 min before perfusion with 4% PFA in 0.1 M PB, 
pH 7.4, as described in the previous section. 20-µm coronal serial sections 
were used to analyze the activation of caspases by detecting the signal of 
SR-FLIVO using a laser confocal microscope (LSM780) with an excitation 
at 565 nm and an emission at 600 nm.225 Functional roles of AMPK in Huntington’s disease • Ju et al.
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by 40 cycles at 95°C for 10 s, 60°C for 5 s, and 72°C for 8 s. At least 
three different batches of cDNA and three independent PCRs were per-
formed and were normalized to the expression of the reference gene   
glyceraldehyde-3-phosphate dehydrogenase (Gapdh). The primers used to 
amplify Bcl2 and Gapdh were 5-GAATGCAAAGCACATCCAATAAA-3 
and 5-TCCAGCATCCCACTCGTA-3 and 5-TGACATCAAGAAGGTGGT-
GAAG-3 and 5-AGAGTGGGAGTTGCTGTTGAAG-3, respectively. The 
data were analyzed using RelQuant software (Roche).
Immunoprecipitation
Brain tissues were lysed with 1 ml of ice-cold RIPA buffer (0.1 M sodium 
phosphate,  10%  sodium  deoxycholate,  100%  Triton  X-100,  and  5  M 
NaCl), incubated for 1 h at 4°C on a rolling wheel to dissolve the tissue, 
and were then incubated with an anti–AMPK-1 or anti–AMPK-2 anti-
body (Novus Biologicals) for 1 h at 4°C. The complexes were then mixed 
with protein A beads (Sigma-Aldrich) and incubated for another 1 h at 
4°C. The immunocomplex was extensively washed with ice-cold RIPA buf-
fer, solubilized in sample treatment buffer (62.5 mM Tris-HCl, pH 6.8, 10% 
glycerol, 2% SDS, and 0.01% bromophenol blue), and analyzed by SDS-
PAGE and Western blot analysis.
Human brain tissue
5-µm brain sections of the human frontal cortex were obtained from the 
National  Institute  of  Child  Health  and  Human  Development  Brain  and   
Tissue Bank for Developmental Disorders, and 5-µm brain sections of the cau-
date nucleus were obtained from the Mayo Clinic College of Medicine. 
The clinical characteristics of subjects are summarized in Table I. At least 
200 cells were counted in brain sections of each subject.
Statistical analysis
The results are expressed as the mean ± SEM of triplicate samples. Each 
experiment was repeated at least three times to confirm the reproducibility 
of the findings. Multiple groups were analyzed with one-way analysis of 
variance followed by a posthoc Student Newman–Keuls test. A p-value of 
<0.05 was considered significant.
Online supplemental material
Fig. S1 shows selective activation and nuclear enrichment of AMPK-1 in 
brains of patients and mice with HD. Fig. S2 shows that an inhibitor of 
AMPK, CC, reduced the nuclear enrichment of AMPK-1 in the striatum 
of R6/2 mice. Fig. S3 shows nuclear enrichment of AMPK-1 in stria-
tal cells expressing polyQ-expanded mHtt. Fig. S4 shows that polyQ-
  expanded mHtt, but not SCA3, causes enrichment of AMPK-1 in striatal 
cells. Fig. S5 shows that AMPK-1 does not interact with the N-terminal 
fragment of Htt. Online supplemental material is available at http://www 
.jcb.org/cgi/content/full/jcb.201105010/DC1.
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